ViiV Healthcare to announce data from largest head-to-head randomised clinical trial for 2-drug regimen Dovato against 3-drug regimen Biktarvy at AIDS 2024

Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain

7th India-Japan medical product regulatory symposium held at New Delhi

Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations

Piramal Pharma’s Ahmedabad facility completes USFDA PAI

Soumya Swaminathan appointed as the Principle Advisor for the National Tuberculosis Elimination Programme

Shilpa Pharma Lifesciences’ Unit 2 Raichur has cleared the ANVISA-Brazil GMP inspection

The Unit has been issued GMP Certification from ANVISA-Brazil

Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution

The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur

KIMS Hospitals acquires 200-bed multi-specialty hospital in Vizag

KIMS already have a multi-specialty hospital and gastro unit at Vizag

Olverembatinib approved for commercialization in Macau China

Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program

Olink announces receipt of CMA clearance for proposed acquisition by Thermo Fisher

Shares and American Depositary Shares of Olink for $26.00 per Share

Shilpa's CDMO customer placed binding purchase order